Payment overview · 2025
General Payments
$338.90
17 reported records · 10 companies
Healthcare provider profile · identity verified
Stephanie Pearson Meyer, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1790045870
Verified facts
What the public records show
CMS Open Payments records show Stephanie Pearson Meyer, M.D. received $338.90 in general payments during 2025 across 17 reported records.
Corcept Therapeutics accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Kerendia, Ozempic.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $51.20 | 15.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $48.95 | 14.4% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $44.32 | 13.1% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.63 | 12.3% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.06 | 10.9% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.90 | 10.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.25 | 7.2% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.18 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.18 | 6.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.23 | 4.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $338.90 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $51.20 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $48.95 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $44.32 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $41.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $37.06 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.25 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $21.18 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.18 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 366 | 106 |
| Amlodipine Besylate | Amlodipine Besylate | 304 | 88 |
| Gabapentin | Gabapentin | 253 | 66 |
| Lisinopril | Lisinopril | 248 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 231 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 63 |
| Omeprazole | Omeprazole | 209 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 150 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 44 |
| Losartan Potassium | Losartan Potassium | 127 | 39 |
| Ezetimibe | Ezetimibe | 118 | 33 |
| Mounjaro | Tirzepatide | 117 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 31 |
| Montelukast Sodium | Montelukast Sodium | 104 | 30 |
| Ozempic | Semaglutide | 104 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 103 | 49 |
| Metformin Hcl Er | Metformin Hcl | 102 | 27 |
| Celecoxib | Celecoxib | 101 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 93 | 31 |
| Trazodone Hcl | Trazodone Hcl | 93 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 89 | 28 |
| Metformin Hcl | Metformin Hcl | 86 | 24 |
| Clonazepam | Clonazepam | 78 | 14 |
| Buspirone Hcl | Buspirone Hcl | 77 | 25 |
| Potassium Chloride | Potassium Chloride | 75 | 29 |
| Furosemide | Furosemide | 74 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 73 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 72 | 20 |
| Alprazolam | Alprazolam | 71 | 21 |
| Carvedilol | Carvedilol | 71 | 22 |
| Famotidine | Famotidine | 71 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 22 |
| Jardiance | Empagliflozin | 70 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 65 | 23 |
| Simvastatin | Simvastatin | 65 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 21 |
| Sertraline Hcl | Sertraline Hcl | 64 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 61 | 21 |
| Farxiga | Dapagliflozin Propanediol | 60 | 18 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 17 |
| Chlorthalidone | Chlorthalidone | 56 | 17 |
| Pregabalin | Pregabalin | 53 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 50 | 17 |
| Meloxicam | Meloxicam | 49 | 13 |
| Eliquis | Apixaban | 48 | suppressed |
| Ibuprofen | Ibuprofen | 45 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | 15 |
| Allopurinol | Allopurinol | 44 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 11 |
| Prednisone | Prednisone | 41 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 40 | suppressed |
| Valsartan | Valsartan | 40 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 11 |
| Meclizine Hcl | Meclizine Hcl | 37 | suppressed |
| Memantine Hcl | Memantine Hcl | 37 | 13 |
| Atenolol | Atenolol | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 14 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | 11 |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 30 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 30 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 25 |
| Azelastine Hcl | Azelastine Hcl | 29 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 25 | 13 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Valacyclovir | Valacyclovir Hcl | 22 | 11 |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | 14 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 17 |
| Lorazepam | Lorazepam | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $338.90 · 17 records | Corcept Therapeutics | AIRSUPRA, CAPVAXIVE, FREESTYLE LIBRE 3, GARDASIL 9, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Veozah, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Kerendia play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error